NCT02574793

Brief Summary

Glucose fluctuations present not only in patients with diabetes mellitus but also in subjects with normal glucose tolerance or impaired glucose regulation. People with Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome are at risk of impaired glucose metabolism. Glycemic variability is poorly studied in the nondiabetic individuals. The aim of the study is to investigate the characteristics of glucose fluctuations in the newly diagnosed Growth Hormone-Secreting Pituitary Adenoma and Cushing Syndrome individuals.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Dec 2014

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2014

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

October 9, 2015

Completed
5 days until next milestone

First Posted

Study publicly available on registry

October 14, 2015

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2017

Completed
7 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 7, 2018

Completed
Last Updated

January 23, 2018

Status Verified

December 1, 2014

Enrollment Period

3.1 years

First QC Date

October 9, 2015

Last Update Submit

January 20, 2018

Conditions

Keywords

Glucose FluctuationGH-Secreting AdenomaCushing Syndrome

Outcome Measures

Primary Outcomes (1)

  • Continuous glucose profiles of mean data of 24-hour continuous glucose monitoring by the CGMS Gold

    The monitoring results consisted of one curve and 5 parameters

    3 days

Secondary Outcomes (4)

  • The mean amplitude of glycemic excursion of newly diagnosed GH adenoma patients

    3 days

  • The mean amplitude of glycemic excursion of newly diagnosed Cushing Syndrome patients during the 3 days monitored by CGMS Gold

    3 days

  • The correlation of MAGE and IGF-1 in newly diagnosed GH adenoma patients

    6 months

  • The correlation of MAGE and cortison in newly diagnosed Cushing Syndrome patients

    6 months

Interventions

Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome

You may qualify if:

  • newly diagnosed GH-releasing pituitary adenoma
  • newly diagnosed Cushing Syndrome

You may not qualify if:

  • history of diabetes mellitus and being treated with drugs
  • being treated with drugs which affect glucose metabolism in the lately 3 months
  • with other hormones affecting glucose metabolism secreted abnormally by pituitary
  • serious comorbidity like malignant tumour, severe hepatosis or nephropathy, serious hypertension(blood pressure\> 180/110mmhg)
  • pregnant or breastfeeding women
  • patients allergic to patches or metal

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Xiaolong Zhao

Jing’an, Shanghai Municipality, 20041, China

Location

MeSH Terms

Conditions

Pituitary NeoplasmsCushing Syndrome

Interventions

Continuous Glucose Monitoring

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHypothalamic NeoplasmsSupratentorial NeoplasmsBrain NeoplasmsCentral Nervous System NeoplasmsNervous System NeoplasmsBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesHypothalamic DiseasesPituitary DiseasesEndocrine System DiseasesAdrenocortical HyperfunctionAdrenal Gland Diseases

Intervention Hierarchy (Ancestors)

Blood Chemical AnalysisClinical Chemistry TestsClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisDiagnostic Techniques, EndocrineMonitoring, PhysiologicInvestigative Techniques

Study Officials

  • yiming li

    director of the endocrinology department

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator, Clinical Associate Professor of Endocrinology department

Study Record Dates

First Submitted

October 9, 2015

First Posted

October 14, 2015

Study Start

December 1, 2014

Primary Completion

December 31, 2017

Study Completion

January 7, 2018

Last Updated

January 23, 2018

Record last verified: 2014-12

Locations